Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.
about
Covariate pharmacokinetic model building in oncology and its potential clinical relevance.Monitoring vigabatrin in head injury patients by cerebral microdialysis: obtaining pharmacokinetic measurements in a neurocritical care setting.Clinical pharmacology = disease progression + drug actionPopulation pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challengesPopulation pharmacokinetics of benznidazole in adult patients with Chagas disease.A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation.Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling.Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's diseasePharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers.Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients.A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's diseaseUnderstanding the time course of pharmacological effect: a PKPD approach.Prediction of drug disposition on the basis of its chemical structure.What do we learn from repeated population analyses?Population pharmacometrics in support of analgesics studies.Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.Population Pharmacokinetic Meta-Analysis of Ramucirumab in Cancer Patients.Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP).Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients.A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients.Evaluation of dosing strategy for pembrolizumab for oncology indications.Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients.The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension.R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.An approach for identifiability of population pharmacokinetic-pharmacodynamic models.Performance comparison of first-order conditional estimation with interaction and Bayesian estimation methods for estimating the population parameters and its distribution from data sets with a low number of subjects.A reduction in between subject variability is not mandatory for selecting a new covariate.Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis.Variation in absorption and half-life of hydrocortisone influence plasma cortisol concentrations.
P2860
Q27687599-BDE5AA68-975E-4AB6-B73A-260C4BF60756Q34570859-24609BB7-68E7-4DD0-B5D0-838634E174DAQ34953659-637BDF28-701E-4A67-B167-998F98E4135EQ34953673-E304D070-46A8-4966-9606-58C8FA221DBEQ34953705-84A9E2D3-567C-42AB-9B96-66AFED29674DQ35607812-BE66E250-D1C0-479C-8A25-F46BEC67A930Q36484557-7183ABB5-AD55-4046-9C49-E9B0B594BF0CQ36702459-6DA44372-D354-4E5E-ADAE-833D2F55BE1EQ36779123-C769FA67-3AF7-46CE-B6BC-94DA0BAF09DEQ36801536-907458B0-1044-4391-8562-303A75B19609Q36933449-76E952A0-774D-4920-97F7-38ED1ED45315Q37184470-F6F45E79-A8F3-4B7C-BFB8-22B584B147DEQ37832754-BF036C9E-2991-4BE0-8C99-A6AE04096902Q38086778-0D82D219-21D2-4237-9500-089AF3FE9366Q38137268-DE3E4EDB-E714-43A1-8A91-EB5C054B0C9EQ38175171-94CE1E25-D69E-49C7-A859-5D2D47A28AFFQ38540353-D84E6D74-9883-428E-ACD9-3FB3A8172F38Q38612237-6807C4D0-6FDE-4FA8-BE1A-A3C273D0CC10Q38667647-B9EE545E-C797-428B-BDC1-85D3188B8B8BQ38759155-BC03CB33-7F0E-4F94-AD0F-83F1E5B2F023Q38765917-1E705BCA-5E7C-45B4-82B0-3B2426F2DD58Q38779793-787F7DFC-A959-44FA-A0D9-C2CD9192DDB9Q38803026-4AC81614-D653-4E44-A2FE-89C728F4BCDCQ38817096-CA96BB26-B2C4-48F6-BD0D-BB57450DFEA4Q38837353-12F64C83-5DDB-4C06-9245-C02AFD9ED50FQ39956114-C5E63548-F573-409D-A25A-BAE22DB06BE4Q40247257-B7F19EA6-5C9C-4F03-BF54-CD5A2614949EQ40769483-865859F1-875A-479B-9914-FD308D89AEDBQ41454640-83BE1098-C473-4B79-BE70-5DB9C72F20B0Q47389644-69CF8294-1A22-40F1-9ACA-BB106E22D0FFQ47414092-F05492A1-EADB-4BE7-9EA2-955848096616Q50460672-849340D3-5D41-4A22-B8A4-A9D2C2BF80B1Q50625224-D15CBE58-F9C5-45DF-AF0C-8D26890E0BEF
P2860
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.
@ast
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.
@en
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.
@nl
type
label
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.
@ast
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.
@en
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.
@nl
prefLabel
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.
@ast
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.
@en
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.
@nl
P2860
P1476
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint
@en
P2093
Daniel F B Wright
Helen R Winter
P2860
P304
P356
10.1111/J.1365-2125.2010.03891.X
P407
P577
2011-06-01T00:00:00Z